Market Closed -
Nasdaq
04:00:00 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
0.7281
USD
|
-1.55%
|
|
-7.84%
|
+5.22%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
177.5
|
45.77
|
17.3
|
18.26
|
-
|
-
|
Enterprise Value (EV)
1 |
32.19
|
-53.31
|
17.3
|
18.26
|
18.26
|
18.26
|
P/E ratio
|
-4.36
x
|
-0.94
x
|
-0.57
x
|
-0.67
x
|
-0.65
x
|
-0.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-4,822,715
x
|
-923,329
x
|
-473,997
x
|
-
|
-
|
-
|
EV / FCF
|
-5,496,715
x
|
-1,163,320
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
30,597
|
30,720
|
24,997
|
25,081
|
-
|
-
|
Reference price
2 |
5.800
|
1.490
|
0.6920
|
0.7281
|
0.7281
|
0.7281
|
Announcement Date
|
3/10/22
|
3/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-19.24
|
-36.8
|
-49.57
|
-36.49
|
-
|
-
|
-
|
EBIT
1 |
-
|
-19.45
|
-37.48
|
-50.19
|
-37.06
|
-38.15
|
-42.11
|
-49.98
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-20.1
|
-36.79
|
-48.59
|
-34.1
|
-34.14
|
-39.77
|
-46.76
|
Net income
1 |
-16.74
|
-20.2
|
-36.79
|
-48.59
|
-34.1
|
-35.34
|
-39.77
|
-46.76
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.160
|
-12.53
|
-1.330
|
-1.580
|
-1.220
|
-1.090
|
-1.115
|
-1.050
|
Free Cash Flow
|
-
|
-18.91
|
-32.28
|
-39.35
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/15/21
|
3/25/21
|
3/10/22
|
3/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-8.007
|
-8.593
|
-
|
-
|
-
|
EBIT
1 |
-10.32
|
-9.413
|
-12.49
|
-10.71
|
-13.94
|
-13.05
|
-11.01
|
-10.18
|
-7.737
|
-8.142
|
-8.73
|
-9.14
|
-9.769
|
-10.52
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.685
|
-9.366
|
-12.4
|
-
|
-13.42
|
-12.23
|
-
|
-
|
-
|
-7.414
|
-7.992
|
-8.258
|
-8.74
|
-9.152
|
Net income
1 |
-9.685
|
-9.366
|
-12.4
|
-10.54
|
-13.42
|
-12.23
|
-10.18
|
-9.386
|
-7.124
|
-7.414
|
-7.992
|
-8.422
|
-9.077
|
-9.852
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3200
|
-0.2700
|
-0.4000
|
-0.3400
|
-0.4400
|
-0.4000
|
-0.3300
|
-0.3100
|
-0.2800
|
-0.3000
|
-0.3200
|
-0.2733
|
-0.2567
|
-0.2700
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/28/23
|
5/9/23
|
8/3/23
|
11/7/23
|
2/28/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
16
|
145
|
99.1
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-18.9
|
-32.3
|
-39.3
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-38.9%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.21
|
2.03
|
0.32
|
-
|
0.18
|
0.18
|
0.18
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/15/21
|
3/25/21
|
3/10/22
|
3/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
0.7281
USD Average target price
4.333
USD Spread / Average Target +495.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.22% | 18.26M | | +15.55% | 121B | | +12.66% | 107B | | -2.53% | 24.82B | | +1.16% | 22.48B | | -8.96% | 18.32B | | -42.28% | 16.33B | | -18.92% | 15.31B | | +6.19% | 14.08B | | +28.83% | 11.74B |
Bio Therapeutic Drugs
|